Dominique Costagliola

发表

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

Vincent Calvez, Christine Katlama, V. Calvez, 2005, AIDS.

When is the epidemic warning cut-off point exceeded?

Dominique Costagliola, 2005, European Journal of Epidemiology.

The unrecognised French BSE epidemic.

D. Costagliola, V. Supervie, Dominique Costagliola, 2004, Veterinary research.

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Anne M Johnson, Hansjakob Furrer, Peter Reiss, 2013, PLoS medicine.

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

Jonathan A C Sterne, Matthias Egger, Caroline A Sabin, 2006, The Lancet.

How was the French BSE epidemic underestimated?

D. Costagliola, V. Supervie, Dominique Costagliola, 2006, Comptes rendus biologies.

When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries

James M Robins, Roger Logan, Jonathan A C Sterne, 2011, Annals of Internal Medicine.

IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia

Brigitte Autran, Roland Tubiana, Christine Katlama, 2003, AIDS.

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)

Roland Tubiana, Vincent Calvez, Christine Katlama, 2004, AIDS.

Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies

Michael Schomaker, Peter Reiss, Amy C. Justice, 2014, PLoS medicine.

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

Pierre-Marie Girard, Françoise Brun-Vézinet, Diane Descamps, 2002, AIDS.

Comparing the public health burden of chronic hepatitis C and HIV infection in France.

John B Wong, Sylvie Deuffic-Burban, A. Valleron, 2004, Journal of hepatology.

Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA

Philippe Katz, Christine Katlama, C. Katlama, 2003, AIDS.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Stephen R Cole, Jonathan A C Sterne, Ross Harris, 2009, The Lancet.

The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2006, Journal of acquired immune deficiency syndromes.

The International Journal of Biostatistics CAUSAL INFERENCE When to Start Treatment ? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data

James M. Robins, Roger Logan, Miguel A. Hernán, 2011 .

Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy

D. Costagliola, S. Grabar, M. Mary-Krause, 2008, AIDS.

Effect estimates in randomized trials and observational studies: comparing apples with apples.

Haitao Chu, Kholoud Porter, Stephen R Cole, 2019, American journal of epidemiology.

The Incubation Period of Kuru

Jean Maccario, Annick Alpérovitch, M. Alpers, 2002, Epidemiology.

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2005, The Journal of infectious diseases.

Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV

D. Costagliola, S. Grabar, G. Pialoux, 2009, AIDS.

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

Brigitte Autran, Laurence Meyer, Asier Sáez-Cirión, 2013, PLoS pathogens.

Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination

Fabrice Carrat, F. Carrat, D. Costagliola, 2017, BMC Medical Research Methodology.

Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns

Victor DeGruttola, Vincent Calvez, Maurizio Zazzi, 2004, Antiviral therapy.

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

David A. Price, Brigitte Autran, Assia Samri, 2007, The Journal of experimental medicine.

Observation plans in longitudinal studies with time-varying treatments

Miguel A. Hernán, Emilie Lanoy, Nuala McGrath, 2009, Statistical methods in medical research.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

Jonathan AC Sterne, Peter Reiss, Caroline A Sabin, 2002, The Lancet.